|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
1997-11-24
|
|
pubmed:abstractText |
This study analyzed the long term results of a combination of dexamethasone, etoposide, ifosfamide, and cisplatin (DVIP) used at the study center as standard second-line combination therapy in patients with aggressive non-Hodgkin's lymphoma (NHL) after prior exposure to doxorubicin.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
80
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1989-96
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:9366303-Adult,
pubmed-meshheading:9366303-Age Factors,
pubmed-meshheading:9366303-Aged,
pubmed-meshheading:9366303-Aged, 80 and over,
pubmed-meshheading:9366303-Agranulocytosis,
pubmed-meshheading:9366303-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9366303-Cisplatin,
pubmed-meshheading:9366303-Dexamethasone,
pubmed-meshheading:9366303-Disease-Free Survival,
pubmed-meshheading:9366303-Etoposide,
pubmed-meshheading:9366303-Female,
pubmed-meshheading:9366303-Humans,
pubmed-meshheading:9366303-Ifosfamide,
pubmed-meshheading:9366303-Lymphoma, Non-Hodgkin,
pubmed-meshheading:9366303-Male,
pubmed-meshheading:9366303-Middle Aged,
pubmed-meshheading:9366303-Salvage Therapy,
pubmed-meshheading:9366303-Treatment Outcome
|
|
pubmed:year |
1997
|
|
pubmed:articleTitle |
Dexamethasone, etoposide, ifosfamide, and cisplatin as second-line therapy in patients with aggressive non-Hodgkin's lymphoma.
|
|
pubmed:affiliation |
Department of Oncology, Rambam Medical Center and Faculty of Medicine, Technion-Israel Institute of Technology, Haifa.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
